

FIJISHI

The Urgent Need for "Outbreak-Speed" Preclinical Validation.

India, 27 April 2025/ 07:29 PM IST

Disclaimer: The following is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, and timing of any features or functionality described for Fijishi's products remains at the sole discretion of Fijishi.

Insight: The Urgent Need for "Outbreak-Speed" Preclinical Validation

Public health research labs operate under immense pressure, especially during emerging infectious disease outbreaks, where every day saved in vaccine development can mean millions of lives impacted.

The ability to achieve a 75% reduction in preclinical validation time for vaccine candidates through intelligent data integration and "digital twin" technology is not merely an efficiency gain; it's a fundamental shift towards an "outbreak-speed" response capability.

The core bottleneck lies in the inherent biological timelines and resource intensity of traditional *in vivo* (animal model) preclinical testing. This creates an unacceptable lag when rapid intervention is paramount, forcing public health to react rather than pre-empt.

Public health researchers are driven by an profound sense of duty to protect global populations. They are motivated by the grim realities of past pandemics and the ethical imperative to provide effective interventions as quickly as humanly possible, minimizing suffering and societal disruption.

Without such acceleration, vaccine development will consistently lag behind viral evolution, resulting in higher morbidity and mortality, prolonged economic and social crises, and a perpetual cycle of crisis management rather than proactive defense against infectious threats.

We must standardize and broadly implement "digital twin" preclinical validation as a critical, early-stage component of rapid response pipelines, enabling public health organizations to effectively mitigate the impact of future pandemics by dramatically accelerating vaccine readiness.

This document is provided for information purposes only. This document is not warranted to be error-free, nor subject to any other warranties or conditions, whether expressed orally or implied in law, including implied warranties and conditions of merchantability or fitness for a particular purpose. We specifically disclaim any liability with respect to this document and no contractual obligations are formed either directly or indirectly by this document. This document may not be reproduced or transmitted in any form or by any means, electronic or mechanical, for any purpose, without our prior written permission. To know more, please visit www.fijishi.com

©2025 Fijishi, and/or its affiliates. All rights reserved.